NRGN and Alzheimer disease: Overall, our results agree with previously studies demonstrating that CSF Ng to be a suitable biomarker for separation of AD patients from controls, as well as reflecting the synaptic degeneration that occurs in brain early in the disease process [4, 9, 34, 35, 41, 50].